Patent ID: 9588119
Date: 2017-03-07
CPC Classifications: C12N,C12Y,G01N

Claim:
1. A method of in vitro inhibiting the growth of radioresistant laryngeal cancer cells, comprising: obtaining a first sample containing human epithelial type 2 (HEp-2) cells; obtaining a second sample containing radioresistant human epithelial type 2 (RR-HEp-2) cells; irradiating the obtained first and second samples with a Cesium-137 source; measuring the protein expression level of ERp57 in the first and second samples; comparing measured expression level of ERp57 in the first sample to the second sample; determining one having higher expression level of Erp57 among the first and the second samples, wherein the protein expression level of ERp57 is upregulated in the RR-Hep-2 cells compared to the Hep-2 cells; and providing a effective amount of an ERp57 inhibitor to the second sample, wherein the growth of radioresistant laryngeal cancer cells is inhibited.